학술논문
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study.
Document Type
Article
Author
Chiricozzi, Andrea; Gori, Niccolò; Narcisi, Alessandra; Balato, Anna; Gambardella, Alessio; Ortoncelli, Michela; Marzano, Angelo Valerio; Balestri, Riccardo; Palazzo, Giovanni; Pellegrino, Michele; Romanelli, Marco; Tripepi, Giovanni; Peris, Ketty; Costanzo, Antonio; ACCURATE Group; Bertoldi, Alberto Maria; Fabbrocini, Gabriella; Fargnoli, Maria Concetta; Girolomoni, Giampiero; Parodi, Aurora
Source
Subject
*ATOPIC dermatitis
*COHORT analysis
*DUPILUMAB
*
*
Language
ISSN
1174-5886
Abstract
Background: The efficacy and safety of upadacitinib in atopic dermatitis (AD) have been defined in clinical trials, but no real-world data are currently available. We aimed to assess the safety and effectiveness of upadacitinib in a real-world AD patient cohort that mostly included patients who failed the available systemic therapies, including dupilumab. Methods: Prospective cohort study collecting data on upadacitinib-treated AD adult patients completing at least 16 weeks of therapy. Results: Forty-three patients showed rapid and marked response to upadacitinib with significant reduction of all disease severity scores since the first follow-up visit. At week 16, Eczema Area and Severity Index (EASI) 75, EASI 90, and EASI 100 response was observed in 97.5%, 82.1%, and 69.2% of patients, respectively. EASI 90 response reflected the achievement of a clear or almost clear condition (POEM 0-2), self-evaluated by 79.5% of patients. Patients' quality of life improved as suggested by the achievement of DLQI 0/1 by 38.5% of patients at week 4, and by 76.9% at week 16. Conclusion: Elevated effectiveness and favorable safety of upadacitinib were confirmed in patients unresponsive to dupilumab, who were not included in upadacitinib trials. [ABSTRACT FROM AUTHOR]